Worryingly, most patients were detected late, when the disease had progressed. Up to 65% of lung cancer patients in Vietnam are diagnosed with stage IIIIV, making the chance of treatment very low. Meanwhile, early diagnosis helps increase the chance of survival, intervene from the beginning and apply appropriate treatment.
Prof. Dr. Nguyen Van Kinh said that treatment should be personalized instead of using a "one for all" approach to improve effectiveness and reduce side effects.
The national strategy for the period 2015-2025 emphasizes the role of prevention, early detection and proactive care.
In this context, Roche's high-value, strategic-focused medical tests play an important role in personalizing treatment, helping to build a pattern based on genetic, environmental and lifestyle factors.
Roche is committed to accompanying the Vietnamese health sector with advanced testing solutions, improving the quality of life for patients.
